Literature DB >> 15282098

Validation of a liquid chromatography assay for the quantification of the Raf kinase inhibitor BAY 43-9006 in small volumes of mouse serum.

Samar Afify1, Ulf R Rapp, Petra Högger.   

Abstract

BAY 43-9006 is a selective Raf-1 kinase inhibitor with antitumor activity against a variety of human cancers. A highly sensitive HPLC method for determination of BAY 43-9006 in small volumes of serum (30 microl) was developed. Sample preparation involved a liquid-liquid extraction procedure with tolnaftate as internal standard followed by linear gradient elution at a reversed phase C18 column and UV detection. The method was selective and the calibration curves were linear over the concentration range of 80-2000 ng/ml. The intra-day accuracy ranged from 99.9 to 107.6% and the inter-day accuracy from 94.6 to 115%. The lower limit of quantitation (LOQ) was 80 ng/ml with an accuracy of 105.8%. Thus, this method has been validated and can be applied for the drug monitoring or pharmacokinetic studies of BAY 43-9006 in small volumes of serum samples.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15282098     DOI: 10.1016/j.jchromb.2004.06.003

Source DB:  PubMed          Journal:  J Chromatogr B Analyt Technol Biomed Life Sci        ISSN: 1570-0232            Impact factor:   3.205


  9 in total

1.  Sequential therapy with JX-594, a targeted oncolytic poxvirus, followed by sorafenib in hepatocellular carcinoma: preclinical and clinical demonstration of combination efficacy.

Authors:  Jeong Heo; Caroline J Breitbach; Anne Moon; Chang Won Kim; Rick Patt; Mi Kyung Kim; Yu Kyung Lee; Sung Yong Oh; Hyun Young Woo; Kelley Parato; Julia Rintoul; Theresa Falls; Theresa Hickman; Byung-Geon Rhee; John C Bell; David H Kirn; Tae-Ho Hwang
Journal:  Mol Ther       Date:  2011-03-22       Impact factor: 11.454

2.  Therapeutic drug monitoring and tyrosine kinase inhibitors.

Authors:  Pauline Herviou; Emilie Thivat; Damien Richard; Lucie Roche; Joyce Dohou; Mélanie Pouget; Alain Eschalier; Xavier Durando; Nicolas Authier
Journal:  Oncol Lett       Date:  2016-06-24       Impact factor: 2.967

3.  Phase I/II study of sorafenib in combination with temsirolimus for recurrent glioblastoma or gliosarcoma: North American Brain Tumor Consortium study 05-02.

Authors:  Eudocia Q Lee; John Kuhn; Kathleen R Lamborn; Lauren Abrey; Lisa M DeAngelis; Frank Lieberman; H Ian Robins; Susan M Chang; W K Alfred Yung; Jan Drappatz; Minesh P Mehta; Victor A Levin; Kenneth Aldape; Janet E Dancey; John J Wright; Michael D Prados; Timothy F Cloughesy; Mark R Gilbert; Patrick Y Wen
Journal:  Neuro Oncol       Date:  2012-10-24       Impact factor: 12.300

4.  Phase I/II study of sorafenib in combination with erlotinib for recurrent glioblastoma as part of a 3-arm sequential accrual clinical trial: NABTC 05-02.

Authors:  Huanwen Chen; John Kuhn; Kathleen R Lamborn; Lauren E Abrey; Lisa M DeAngelis; Frank Lieberman; H Ian Robins; Susan M Chang; W K Alfred Yung; Jan Drappatz; Minesh P Mehta; Victor A Levin; Kenneth Aldape; Janet E Dancey; John J Wright; Michael D Prados; Timothy F Cloughesy; Patrick Y Wen; Mark R Gilbert
Journal:  Neurooncol Adv       Date:  2020-09-17

5.  Preparation, in vitro release, and pharmacokinetics in rabbits of lyophilized injection of sorafenib solid lipid nanoparticles.

Authors:  Hong Zhang; Fu-Ming Zhang; Shi-Jun Yan
Journal:  Int J Nanomedicine       Date:  2012-06-18

6.  Pharmacokinetic Interaction between Sorafenib and Atorvastatin, and Sorafenib and Metformin in Rats.

Authors:  Agnieszka Karbownik; Danuta Szkutnik-Fiedler; Andrzej Czyrski; Natalia Kostewicz; Paulina Kaczmarska; Małgorzata Bekier; Joanna Stanisławiak-Rudowicz; Marta Karaźniewicz-Łada; Anna Wolc; Franciszek Główka; Edmund Grześkowiak; Edyta Szałek
Journal:  Pharmaceutics       Date:  2020-06-28       Impact factor: 6.321

7.  Use of mitogenic cascade blockers for treatment of C-Raf induced lung adenoma in vivo: CI-1040 strongly reduces growth and improves lung structure.

Authors:  Boris W Kramer; Rudolf Götz; Ulf R Rapp
Journal:  BMC Cancer       Date:  2004-06-01       Impact factor: 4.430

8.  In vivo assessment of the drug interaction between sorafenib and paracetamol in rats.

Authors:  Agnieszka Karbownik; Katarzyna Sobańska; Tomasz Grabowski; Joanna Stanisławiak-Rudowicz; Anna Wolc; Edmund Grześkowiak; Edyta Szałek
Journal:  Cancer Chemother Pharmacol       Date:  2020-05-11       Impact factor: 3.333

9.  Pharmacokinetic Drug Interaction Study of Sorafenib and Morphine in Rats.

Authors:  Agnieszka Karbownik; Danuta Szkutnik-Fiedler; Tomasz Grabowski; Anna Wolc; Joanna Stanisławiak-Rudowicz; Radosław Jaźwiec; Edmund Grześkowiak; Edyta Szałek
Journal:  Pharmaceutics       Date:  2021-12-16       Impact factor: 6.321

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.